Cabaletta Bio Inc (CABA) - Net Assets
Based on the latest financial reports, Cabaletta Bio Inc (CABA) has net assets worth $112.05 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($165.08 Million) and total liabilities ($53.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Cabaletta Bio Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $112.05 Million |
| % of Total Assets | 67.88% |
| Annual Growth Rate | N/A |
| 5-Year Change | -5.01% |
| 10-Year Change | N/A |
| Growth Volatility | 55.07 |
Cabaletta Bio Inc - Net Assets Trend (2017–2025)
This chart illustrates how Cabaletta Bio Inc's net assets have evolved over time, based on quarterly financial data. Also explore Cabaletta Bio Inc asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Cabaletta Bio Inc (2017–2025)
The table below shows the annual net assets of Cabaletta Bio Inc from 2017 to 2025. For live valuation and market cap data, see CABA company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $112.05 Million | -26.44% |
| 2024-12-31 | $152.34 Million | -35.51% |
| 2023-12-31 | $236.20 Million | +125.98% |
| 2022-12-31 | $104.52 Million | -11.39% |
| 2021-12-31 | $117.96 Million | +7.68% |
| 2020-12-31 | $109.54 Million | -20.80% |
| 2019-12-31 | $138.32 Million | +1393.93% |
| 2018-12-31 | $-10.69 Million | -4193.17% |
| 2017-12-31 | $-249.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cabaletta Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 51670700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $25.00K | 0.02% |
| Other Components | $628.98 Million | 561.34% |
| Total Equity | $112.05 Million | 100.00% |
Cabaletta Bio Inc Competitors by Market Cap
The table below lists competitors of Cabaletta Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangzhou Jet Bio-Filtration Co Ltd
SHG:688026
|
$327.40 Million |
|
Vivien Corp
KO:002070
|
$327.51 Million |
|
Sinpas Gayrimenkul Yatirim Ortakligi AS
IS:SNGYO
|
$327.63 Million |
|
Anhui Hyea Aromas Co Ltd
SHE:300886
|
$327.81 Million |
|
CapMan Oyj B
HE:CAPMAN
|
$327.18 Million |
|
SillaJen Inc
KQ:215600
|
$327.16 Million |
|
Summit Midstream Corporation
NYSE:SMC
|
$327.15 Million |
|
Haverty Furniture Companies Inc
NYSE:HVT
|
$327.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cabaletta Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 152,335,000 to 112,051,000, a change of -40,284,000 (-26.4%).
- Net loss of 167,856,000 reduced equity.
- Share repurchases of 291,000 reduced equity.
- New share issuances of 106,303,000 increased equity.
- Other comprehensive income increased equity by 25,000.
- Other factors increased equity by 21,535,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-167.86 Million | -149.8% |
| Share Repurchases | $291.00K | -0.26% |
| Share Issuances | $106.30 Million | +94.87% |
| Other Comprehensive Income | $25.00K | +0.02% |
| Other Changes | $21.54 Million | +19.22% |
| Total Change | $- | -26.44% |
Book Value vs Market Value Analysis
This analysis compares Cabaletta Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.68x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.01 | $2.94 | x |
| 2018-12-31 | $-0.74 | $2.94 | x |
| 2019-12-31 | $25.29 | $2.94 | x |
| 2020-12-31 | $4.73 | $2.94 | x |
| 2021-12-31 | $4.58 | $2.94 | x |
| 2022-12-31 | $3.56 | $2.94 | x |
| 2023-12-31 | $5.77 | $2.94 | x |
| 2024-12-31 | $3.08 | $2.94 | x |
| 2025-12-31 | $1.10 | $2.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cabaletta Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -149.80%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.47x
- Recent ROE (-149.80%) is below the historical average (-42.58%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-225.10K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.13 Million |
| 2019 | -10.92% | 0.00% | 0.00x | 1.02x | $-28.93 Million |
| 2020 | -29.66% | -324910000000.00% | 0.00x | 1.05x | $-43.45 Million |
| 2021 | -38.60% | 0.00% | 0.00x | 1.07x | $-57.33 Million |
| 2022 | -49.57% | 0.00% | 0.00x | 1.12x | $-62.26 Million |
| 2023 | -28.65% | 0.00% | 0.00x | 1.07x | $-91.29 Million |
| 2024 | -76.06% | 0.00% | 0.00x | 1.21x | $-131.10 Million |
| 2025 | -149.80% | 0.00% | 0.00x | 1.47x | $-179.06 Million |
Industry Comparison
This section compares Cabaletta Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cabaletta Bio Inc (CABA) | $112.05 Million | 0.00% | 0.47x | $327.29 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immu… Read more